Advicenne S.A.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a ALDVI.PA research report →
About the company
Advicenne S. A. operates as a specialized pharmaceutical firm, focusing on the innovation and commercialization of therapeutic solutions for various kidney-related disorders.
- CEO
- Laurent Cassedanne
- IPO
- 2017
- Employees
- 21
- HQ
- Paris, FR
Price Chart
- Market Cap
- $14.66M
- P/E
- -1.40
- P/S
- 2.44
- P/B
- -0.55
- EV/EBITDA
- -4.94
- Div Yield
- 0.00%
- Gross Margin
- -35.71%
- Op Margin
- -139.14%
- Net Margin
- -158.71%
- ROE
- 37.85%
- ROIC
- 132.82%
- Revenue
- $6.01M · 20.77%
- Net Income
- $-9,532,000 · -47.46%
- EPS
- $-0.72 · -35.85%
- Op Income
- $-8,356,999
- FCF YoY
- -381.71%
- 52W High
- $2.35
- 52W Low
- $0.80
- 50D MA
- $1.10
- 200D MA
- $1.59
- Beta
- 0.96
- Avg Volume
- 50.43K
Get TickerSpark's AI analysis on ALDVI.PA
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Our ALDVI.PA coverage
Recent articles, reports, and earnings notes.
No research on ALDVI.PA yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate ALDVI.PA report →Similar companies
Peers in the same neighborhood.